Provided by Tiger Trade Technology Pte. Ltd.

BioCardia

1.12
+0.02001.82%
Volume:103.45K
Turnover:114.52K
Market Cap:16.96M
PE:-1.51
High:1.14
Open:1.12
Low:1.08
Close:1.10
52wk High:2.27
52wk Low:0.7500
Shares:15.14M
Float Shares:12.12M
Volume Ratio:1.31
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7393
EPS(LYR):-1.2341
ROE:-1803.19%
ROA:-134.97%
PB:6.28
PE(LYR):-0.91

Loading ...

BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250

Reuters
·
Jun 10

BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 09

BioCardia Raises $4.4 Million to Extend Cash Runway

TIPRANKS
·
Jun 08

BioCardia - Net Proceeds Expected to Extend Cash Runway Into Q1 2027

THOMSON REUTERS
·
Jun 08

Press Release: BioCardia Announces $4.4 Million Financing

Dow Jones
·
Jun 08

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06

Top Midday Gainers

MT Newswires Live
·
Jun 06

BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia

Reuters
·
Jun 05

BioCardia Gains FDA Path for CardiAMP PMA Approval

TIPRANKS
·
Jun 05

FDA confirms CardiAMP Heart Failure II Trial may support premarket approval

TIPRANKS
·
Jun 05

BioCardia says FDA confirms CardiAMP HF II trial may support PMA for CardiAMP cell therapy in ischemic HFrEF

Reuters
·
Jun 05

FDA Confirms Cardiamp HF Ii May Support Premarket Approval of Cardiamp Cell Therapy for Ischemic Hfref

THOMSON REUTERS
·
Jun 05

BioCardia says Japan PMDA advice clears path for CardiAMP approval filing in ischemic heart failure

Reuters
·
May 28

BioCardia Announces Japan Pmda Record of Advice Supports Regulatory Submission for Approval of Cardiamp Cell Therapy for Ischemic Heart Failure

THOMSON REUTERS
·
May 28

BioCardia CEO Peter Altman acquires common shares worth $1,570.00

Reuters
·
May 22

BioCardia reports CardiAMP trial improves exercise tolerance in chronic myocardial ischemia patients

Reuters
·
May 21

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

GlobeNewswire
·
May 21

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

GlobeNewswire
·
May 19

BioCardia CEO Peter Altman acquires 5,700 shares valued at $5,244

Reuters
·
May 19

BioCardia Earnings Call: Progress, Promise and Cash Strain

TIPRANKS
·
May 19